Objective : To conduct the budget impact analysis of health insurance on Recombinant Human Tumor Necrosis Factor－α ReceptorⅡ：IgG Fc Fusion Protein (rhTNFR:Fc). Methods: Rheumatic drugs were select from the IMS data 2015. The drug quantity unit was converted to defined daily dose (DDD). The quantity of rhTNFR: FC in IMS data 2015 was taken as the baseline. The expenditure growth and its impact on rheumatic drugs and all drugs were calculated under 90% and 80% reimbursement rate as the different incremental proportion of the quantity of rhTNFR:Fc. National health insurance expenditure data is derived from statistical data of government departments. Results: Health insurance expenditure increases about 5.22~10.43 billion CNY, rheumatic drugs and all drugs expenditure increase 63.44~126.87% and 0.04~0.08% respectively when the consumption of rhTNFR:Fc increases 0-100% based on 2015 under 90% reimbursement rate. The increment of health insurance expenditure is reduced accordingly under the reimbursement ratio of 80%. Conclusions: The budget impact of rhTNFR:Fc is great on rheumatic drugs, but is very limited on all drugs.